Skip to content
Subscriber Only

Takeda Clears Hurdle for $62 Billion Shire Deal

  • Approval gives boost to CEO’s efforts to win over shareholders
  • Acquisition likely faces tougher antitrust scrutiny in Europe
Shire Plc Medicines As AbbVie Inc. Raises Offer To $51.5 Billion

Photographer: Chris Ratcliffe/Bloomberg

Updated on

Takeda Pharmaceutical Co. cleared a hurdle for its $62 billion acquisition of Shire Plc, receiving unconditional approval from the U.S. Federal Trade Commission two months after sealing its biggest deal ever.

The purchase remains subject to a number of conditions, the Japanese company said in a statement Tuesday, including other regulatory clearances and approval by shareholders of both companies.